Further studies in larger cohorts of patients with different phenotypes of AD are needed to more conclusively assess the prevalence of functional autoantibodies to IgE or FcεRI and their possible contribution to disease pathogenesis and the response to current and prospective therapeutic strategies. This evidence concerns the gene IGHE and Alzheimer disease.